- Rituximab is used for many autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, as well as cancer.
- It binds CD20 on B cells, which results in recruitment of other immune cells and destruction of the B cells.
- It is administered through intravenous infusion every 6 months.
- Sales in 2016 were €1.4 billion in Europe.
- It has a very low immunogenicity rates, only about 10%.
Labs that test for drug level:
Labs that test for ADA titre: